A citation-based method for searching scientific literature

J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera, J L Anderson, M Pirmohamed, T E Klein, N A Limdi, L H Cavallari, M Wadelius. Clin Pharmacol Ther 2017
Times Cited: 233







List of co-cited articles
645 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
528
28

Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
24

A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
496
22

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
392
22

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
538
21

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Brian F Gage, Anne R Bass, Hannah Lin, Scott C Woller, Scott M Stevens, Noor Al-Hammadi, Juan Li, Tomás Rodríguez, J Philip Miller, Gwendolyn A McMillin,[...]. JAMA 2017
122
21

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
201
20

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
419
16

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
539
15

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
167
15

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
146
15

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
B Moriyama, A Owusu Obeng, J Barbarino, S R Penzak, S A Henning, S A Scott, Jag Agúndez, J R Wingard, H L McLeod, T E Klein,[...]. Clin Pharmacol Ther 2017
122
15


The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden,[...]. Clin Pharmacol Ther 2014
210
14

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Kelly E Caudle, Teri E Klein, James M Hoffman, Daniel J Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M McDonagh, Katrin Sangkuhl, Caroline F Thorn, Matthias Schwab,[...]. Curr Drug Metab 2014
203
14

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
K E Caudle, A E Rettie, M Whirl-Carrillo, L H Smith, S Mintzer, M T M Lee, T E Klein, J T Callaghan. Clin Pharmacol Ther 2014
136
13

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
353
12

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Jessica L Mega, Joseph R Walker, Christian T Ruff, Alexander G Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A Murphy, James Lee, Michele F Mercuri, Robert P Giugliano,[...]. Lancet 2015
112
12

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
884
12

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio,[...]. Clin Pharmacol Ther 2018
154
11

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
K A Birdwell, B Decker, J M Barbarino, J F Peterson, C M Stein, W Sadee, D Wang, A A Vinks, Y He, J J Swen,[...]. Clin Pharmacol Ther 2015
252
11


Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
574
11

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
G C Bell, K E Caudle, M Whirl-Carrillo, R J Gordon, K Hikino, C A Prows, A Gaedigk, Jag Agundez, S Sadhasivam, T E Klein,[...]. Clin Pharmacol Ther 2017
76
13

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam,[...]. Clin Pharmacol Ther 2014
368
10

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Victoria M Pratt, Larisa H Cavallari, Andria L Del Tredici, Houda Hachad, Yuan Ji, Ann M Moyer, Stuart A Scott, Michelle Whirl-Carrillo, Karen E Weck. J Mol Diagn 2019
29
34

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
203
10

A global reference for human genetic variation.
Adam Auton, Lisa D Brooks, Richard M Durbin, Erik P Garrison, Hyun Min Kang, Jan O Korbel, Jonathan L Marchini, Shane McCarthy, Gil A McVean, Gonçalo R Abecasis. Nature 2015
10

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Katherine N Theken, Craig R Lee, Li Gong, Kelly E Caudle, Christine M Formea, Andrea Gaedigk, Teri E Klein, José A G Agúndez, Tilo Grosser. Clin Pharmacol Ther 2020
41
24

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
M Verbelen, M E Weale, C M Lewis. Pharmacogenomics J 2017
90
10

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
259
9

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
119
9

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Larisa H Cavallari, Craig R Lee, Amber L Beitelshees, Rhonda M Cooper-DeHoff, Julio D Duarte, Deepak Voora, Stephen E Kimmel, Caitrin W McDonough, Yan Gong, Chintan V Dave,[...]. JACC Cardiovasc Interv 2018
136
9

The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
404
8

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
251
8

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Elizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan-Tsong Chen, Bruce C Carleton, Alfred L George,[...]. Clin Pharmacol Ther 2018
89
8

Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.
W S Bush, D R Crosslin, A Owusu-Obeng, J Wallace, B Almoguera, M A Basford, S J Bielinski, D S Carrell, J J Connolly, D Crawford,[...]. Clin Pharmacol Ther 2016
93
8


Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.
Nicholas L Syn, Andrea Li-Ann Wong, Soo-Chin Lee, Hock-Luen Teoh, James Wei Luen Yip, Raymond Cs Seet, Wee Tiong Yeo, William Kristanto, Ping-Chong Bee, L M Poon,[...]. BMC Med 2018
18
44

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
783
8

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Hsiang-Yu Yuan, Jin-Jer Chen, M T Michael Lee, Ju-Chieh Wung, Ying-Fu Chen, Min-Ji Charng, Ming-Jen Lu, Chi-Ren Hung, Chun-Yu Wei, Chien-Hsiun Chen,[...]. Hum Mol Genet 2005
357
7

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
777
7

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
448
7

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
M V Relling, E M McDonagh, T Chang, K E Caudle, H L McLeod, C E Haidar, T Klein, L Luzzatto. Clin Pharmacol Ther 2014
53
13

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
996
7

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Jacob T Brown, Jeffrey R Bishop, Katrin Sangkuhl, Erika L Nurmi, Daniel J Mueller, Jean C Dinh, Andrea Gaedigk, Teri E Klein, Kelly E Caudle, James T McCracken,[...]. Clin Pharmacol Ther 2019
47
14

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
R A Wilke, L B Ramsey, S G Johnson, W D Maxwell, H L McLeod, D Voora, R M Krauss, D M Roden, Q Feng, R M Cooper-Dehoff,[...]. Clin Pharmacol Ther 2012
215
7

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.
S L Van Driest, Y Shi, E A Bowton, J S Schildcrout, J F Peterson, J Pulley, J C Denny, D M Roden. Clin Pharmacol Ther 2014
164
7

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Kelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, Jesse J Swen, Cyrine E Haidar, Teri E Klein, Roseann S Gammal, Mary V Relling, Stuart A Scott, Daniel L Hertz,[...]. Clin Transl Sci 2020
120
7

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.
Matthias Samwald, Hong Xu, Kathrin Blagec, Philip E Empey, Daniel C Malone, Seid Mussa Ahmed, Patrick Ryan, Sebastian Hofer, Richard D Boyce. PLoS One 2016
35
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.